Cytokinetics Stock News

After the company disclosed that the Food and Drug Administration has awarded fast-track status to its lead drug candidate, omecamtiv mecarbil, shares in Cytokinetics (NASDAQ: CYTK) are surging 24.5%

FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure | STL.News | Read business news and more at STL.News.

Amgen (AMGN) and Cytokinetics, Incorporated (CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac

Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel sel

CYTK earnings call for the period ending March 31, 2020.

Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. Due

Q1 2020 Cytokinetics Inc Earnings Call

CK Infrastructure Holdings <1083.HK> and unit Power Assets Holdings <0006.HK> said the firms expect a material reduction in their first-half net profit compared to a year ago, due to the re-measuremen

Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif., May 06,.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

A sense of cautious optimism is looming over the Street given the progress in the reopening of the U.S. economy, and while the recent uptick isn’t necessarily indicative of a full recovery, it’s c